BMS’s Deucravacitinib Superior to Otezla (apremilast) and Placebo in POETYK PSO-2 Psoriasis Trial
Bristol-Myers Squibb announced positive results from POETYK PSO-2, the second pivotal Phase 3 trial evaluating deucravacitinib for the treatment of […]